M. Goerner

发表

The use of granulocyte colony-stimulating factor during retroviral transduction on fibronectin fragment CH-296 enhances gene transfer into hematopoietic repopulating cells in dogs.

R. Storb, P. Mcsweeney, H. Kiem, 1999, Blood.

Highly Efficient Expansion of Human CD4+CD25+ Regulatory T Cells for Cellular Immunotherapy in Patients with Graft-Versus-Host Disease

A. Ho, M. Munder, Markus Schneider, 2006, Journal of immunotherapy.

Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity.

A. Ho, J. M. Fuentes, F. Mollinedo, 2005, Blood.

Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).

A. Hinke, F. Kauff, B. Hertenstein, 2016 .

Expansion and transduction of nonenriched human cord blood cells using HS-5 conditioned medium and FLT3-L.

S. Heimfeld, H. Kiem, B. Torok-Storb, 2000, Journal of hematotherapy & stem cell research.

Purified canine CD34+Lin- marrow cells transduced with retroviral vectors give rise to long-term multi-lineage hematopoiesis.

R. Storb, P. Mcsweeney, R. Nash, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The use of CD34+-selected PBPC after high-dose chemotherapy in breast cancer patients is associated with prolonged recovery time and increased infectious complications.

H. Wandt, J. Birkmann, K. Schäfer-Eckart, 1999, Journal of hematotherapy & stem cell research.

Inolimomab in Steroid-Refractory Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis and Comparison with Other Interleukin-2 Receptor Antibodies

A. Fischer, A. Stamatoullas, I. Yakoub-Agha, 2005, Transplantation.

Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias.

K. Sullivan, R. Storb, H. Kiem, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Addition of a low fixed number of CD3+ cells to CD34-enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation.

T. Luft, A. Ho, A. Benner, 2003, Journal of hematotherapy & stem cell research.

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Sustained multilineage gene persistence and expression in dogs transplanted with CD34(+) marrow cells transduced by RD114-pseudotype oncoretrovirus vectors.

J. Rasko, R. Storb, P. Horn, 2001, Blood.

Improved gene transfer into canine hematopoietic repopulating cells using CD34-enriched marrow cells in combination with a gibbon ape leukemia virus–pseudotype retroviral vector

R. Storb, A. Miller, P. Mcsweeney, 1999, Gene Therapy.

vectors with CD34+ marrow cells transduced by RD114-pseudotype oncoretrovirus Sustained multilineage gene persistence and expression in dogs transplanted

J. Rasko, R. Storb, P. Horn, 2013 .

Direct comparison of steady-state marrow, primed marrow, and mobilized peripheral blood for transduction of hematopoietic stem cells in dogs.

H. Kiem, Jesse Thompson, L. Peterson, 2003, Human gene therapy.

Painful Spinal Cord Compression as a Complication of Extramedullary Hematopoiesis Associated with β-Thalassemia Intermedia

S. Gerull, P. Hirnle, M. Goerner, 2008, Strahlentherapie und Onkologie.

Molecular targeted therapies in head and neck cancer - An update of recent developements -

Holger Sudhoff, H. Sudhoff, T. Seiwert, 2010, Head & neck oncology.

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients wi

D. Hose, H. Goldschmidt, A. Jauch, 2016, BMC Cancer.

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

D. Hose, H. Goldschmidt, A. Jauch, 2021, Cancers.

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood Cancer Journal.

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

D. Hose, H. Goldschmidt, A. Jauch, 2021, Blood cancer journal.

ABO blood group barrier in allogeneic bone marrow transplantation revisited.

A. Barrett, M. Horowitz, R. Gale, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A. Ho, A. Benner, M. Goerner, 2003, Journal of hematotherapy & stem cell research.

Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma

H. Goldschmidt, A. Benner, U. Hegenbart, 2005, Bone Marrow Transplantation.

The initial phase of graft-versus-host disease is associated with a decrease of CD4+CD25+ regulatory T cells in the peripheral blood of patients after allogeneic stem cell transplantation.

A. Ho, M. Munder, S. Karakhanova, 2006, Clinical and laboratory haematology.

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

R. Greil, C. Buske, A. Hinke, 2019, Blood.

Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma.

H. Goldschmidt, T. Luft, A. Ho, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Adaptive functional differentiation of dendritic cells: integrating the network of extra- and intracellular signals.